Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data
Objective: To assess the real-world safety profile of Gocovri® (amantadine) extended release capsules one year post-launch. Background: Gocovri received FDA approval in August 2017 for…High dose amantadine therapy may cause increased falling in Parkinson’s patients
Objective: To report a possible association between high dose amantadine and increased falling in patients with Parkinson’s disease (PD). Background: Amantadine is used in PD…Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: The primary objective of this study was the safety and tolerability of ADS-5102 in PD patients with dyskinesia. Secondary efficacy outcome measures included MDS-UPDRS,…Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials
Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients
Objective: This economic evaluation projects the likely cost-effectiveness of ADS-5102 in comparison to the current standard of best supportive care. Background: In August, 2017, the…Amantadine extended release (Gocovri) reduces dyskinesia and bradykinesia: Evaluation of clinical response with the wearable PKG (Personal Kinetigraph) watch
Objective: To determine the effect of bedtime high-dose amantadine extended release (Gocovri) in 50 consecutive patients experiencing motor fluctuations and dyskinesia. Background: Amantadine extended release…Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period
Objective: To study the possibility of using dopaminergic medicines for the treatment of Bell`s paralysis in acute period. Background: In previous reports we conjectured that…Interim Results of an Ongoing Open-label Safety Study of ADS-5102 (amantadine hydrochloride) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)
Objective: Characterize the long-term safety and tolerability of 340 mg of ADS-5102 administered once daily at bedtime, for the treatment of LID in Parkinson’s disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.